The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:1187-1188 September 18, 2003 Number 12
NextNext

Radiotherapy for Advanced Hodgkin's Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Aleman, B. M.P.
-PubMed Citation
To the Editor: We disagree with Aleman et al. (June 12 issue)1 that involved-field radiotherapy does not improve the outcome after a complete response to chemotherapy in patients with advanced Hodgkin's lymphoma. The authors used two additional cycles of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV) as consolidation chemotherapy after a complete response had been achieved. Not surprisingly, involved-field radiotherapy failed to improve the outcome. Had they performed randomization immediately after the achievement of a complete response, the benefit of radiation might have been evident.

The Children's Cancer Group (CCG) trial,2 in which 501 patients with a complete . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.